Latest Trials

EudraCT Number: 2022-003588-55 Sponsor Protocol Number: 20221102 Start Date: 2024-10-14
Sponsor Name: Isala
Full Title: Evaluating the safety of shortened infusion tiMes for dIfferent oNcological immUnoThErapies; An observational prospective study
Medical condition: Oncology
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: NL (Trial now transitioned)
Trial results: (No results available)
EudraCT Number: 2021-004755-17 Sponsor Protocol Number: MYST-FACT Start Date: 2024-10-01
Sponsor Name: FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO
Full Title: PHASE I/II CLINICAL TRIAL OF ALLOGENEIC BONE MARROW DERIVED MESENCHYMAL STROMAL CELL THERAPY FOR THE PREVENTION AND TREATMENT OF PULMONARY FIBROSIS SECONDARY TO POST-INFECTIVE ARDS OR ALLOIMMUNE RE...
Medical condition: PULMONARY FIBROSIS SECONDARY TO ARDS OR ALLOIMMUNE REACTION AFTER TRANSPLANTATION
Disease: Version SOC Term Classification Code Term Level
21.1 100000004855 10022619 Interstitial pulmonary fibrosis LLT
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
Trial protocol: IT (Prematurely Ended)
Trial results: (No results available)
EudraCT Number: 2022-002770-82 Sponsor Protocol Number: RR202200317 Start Date: 2024-09-09
Sponsor Name: Universitair Medisch Centrum Groningen
Full Title: The use of FAPI-PET/CT scan and FDG-PET?CT scan in acute phase Peyronie's disease for detection of active fibroblasts and inflammation in the penis - a pilot study
Medical condition: Peyronie's disease
Disease: Version SOC Term Classification Code Term Level
21.1 10038604 - Reproductive system and breast disorders 10034766 Peyronies disease LLT
Population Age: Elderly Gender: Male
Trial protocol: NL (Trial now transitioned)
Trial results: (No results available)
EudraCT Number: 2018-002373-22 Sponsor Protocol Number: hNSCALSII Start Date: 2024-05-31
Sponsor Name: FONDAZIONE CASA SOLLIEVO DELLA SOFFERENZA OPERA DI SAN PIO DA PIETRELCINA OSPEDALE IRCCS
Full Title: Neural Stem Cell Treatment for Amyotrophic Lateral Sclerosis: A multicenter, randomized placebo controlled and biological endpoints clinical Trial
Medical condition: Amyotrophic Lateral Sclerosis (ALS)
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults Gender: Male, Female
Trial protocol: IT (Trial now transitioned)
Trial results: (No results available)
EudraCT Number: 2007-001152-39 Sponsor Protocol Number: SSG XX Start Date: 2024-05-21
Sponsor Name: Scandinavian Sarcoma Group
Full Title: SSGXX A Scandinavian Sarcoma Group treatment protocol for adult patients with non-metastatic high-risk soft tissue sarcoma of the extremities and trunk wall
Medical condition: SSG XX is a phase II trial for high-risk soft tissue sarcoma(STS) of the extremities and trunk wall. Prognostic markers are used to identify high-risk tumors. SSG XX will evaluate chemo-and radioth...
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: NO (Completed) SE (Completed)
Trial results: (No results available)
EudraCT Number: 2020-004231-25 Sponsor Protocol Number: MS201923_0050 Start Date: 2024-05-21
Sponsor Name: Merck Healthcare KGaA
Full Title: A Phase II, open-label, single-arm study of berzosertib (M6620) in combination with topotecan in participants with relapsed platinum-resistant small-cell lung cancer
Medical condition: Relapsed platinum resistant small-cell lung cancer
Disease: Version SOC Term Classification Code Term Level
21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: FR (Completed) IT (Completed) ES (Temporarily Halted)
Trial results: (No results available)
EudraCT Number: 2020-004633-21 Sponsor Protocol Number: APHP191047 Start Date: 2024-04-29
Sponsor Name: Assistance Publique -Hopitaux de Paris
Full Title:
Medical condition:
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: FR (Trial now transitioned)
Trial results: (No results available)
EudraCT Number: 2020-003745-11 Sponsor Protocol Number: 1346-0014 Start Date: 2024-03-02
Sponsor Name: Boehringer Ingelheim
Full Title: An open label, single arm, extension trial to examine long-term safety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials.(CONNEX-X)
Medical condition: Schizophrenia
Disease: Version SOC Term Classification Code Term Level
20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
Population Age: Adults Gender: Male, Female
Trial protocol: FR (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) SK (Trial now transitioned) HU (Trial now transitioned) NO (Trial now transitioned) DK (Trial now transitioned) LT (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) BE (Trial now transitioned) SE (Trial now transitioned) NL (Trial now transitioned) FI (Trial now transitioned) HR (Trial now transitioned) AT (Trial now transitioned) BG (Ongoing) PT (Trial now transitioned) RO (Trial now transitioned)
Trial results: (No results available)
EudraCT Number: 2023-000005-12 Sponsor Protocol Number: CRCFC-TEICO.SA.2022 Start Date: 2024-02-21
Sponsor Name: AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA
Full Title: An open-label study to evaluate the safety and tolerability of inhaled Teicoplanin in the treatment of Staphylococcus aureus (including mrsa) infections in CYSTIC FIBROSIS PATIENTS
Medical condition: cystic fibrosis associated to persistent Staphylococcus aureus (including MRSA) infection
Disease: Version SOC Term Classification Code Term Level
20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
20.0 100000004862 10075981 Staphylococcus aureus infection LLT
Population Age: Adolescents, Under 18, Adults Gender: Male, Female
Trial protocol: IT (Trial now transitioned)
Trial results: (No results available)
EudraCT Number: 2022-003922-27 Sponsor Protocol Number: PAM-UMCG-002 Start Date: 2024-02-08
Sponsor Name: University Medical Center Groningen (UMCG)
Full Title: Neo-adjuvant Pembrolizumab as alternative to radio(chemo)therapy in MMRd uterine cancer
Medical condition: Primary uterine cancer characterized with dMMR
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Female
Trial protocol: NL (Ongoing)
Trial results: (No results available)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe